Ex Vivo Culture of Patient-Derived Primary, Metastatic, and Post-Mortem Lung Cancer Reveals Targetable States of EMT and Metabolic Plasticity
Acevedo-Acevedo, S.; Ackerman, H. D.; Rubio, V. Y.; Hackel, N.; Carr, C. L.; Miranda, K. A.; Baldwin, J. R.; Reiser, M.; Lockhart, J. H.; Lui, A.; Stewart, P. A.; Yu, X.; Wright, G. M.; Alontaga, A. Y.; Koomen, J. M.; Nguyen, D. T.; Sawyer, W. G.; DeNicola, G. M.; Boyle, T.; Cress, W. D.; Haura, E. B.; Flores, E. R.
Show abstract
Lung cancer is a highly heterogeneous disease and remains the leading cause of cancer-related mortality worldwide. While mouse models and patient-derived organoids have advanced our understanding of lung cancer, key interactions within the tumor microenvironment (TME) remain poorly characterized. We developed microtumor models from lung adenocarcinoma (LUAD) and small cell lung cancer (SCLC) using mouse and patient samples, including surgical resections and rapid autopsy specimens. Microtumors preserve structural, cellular, and molecular features of the native TME, enabling mechanistic studies of tumor progression ex vivo. Multi-omics analyses of LUAD microtumors revealed progression-associated changes, including increased epithelial-to-mesenchymal transition (EMT) and metabolic reprogramming toward fatty acid synthesis. Pharmacologic inhibition of fatty acid synthesis through ACC1/2 reduced proliferation in patient-derived microtumors, identifying a targetable vulnerability. This platform provides a robust system for studying tumor progression, therapeutic response, and resistance mechanisms in lung cancer, including culturing postmortem specimens that are not accessible in current models.
Matching journals
The top 10 journals account for 50% of the predicted probability mass.